PARIS--(BUSINESS WIRE)-- Characterization of Circulating Tumor Cells (CTCs) is a compelling challenge for cancer researchers and clinical trial managers because of the high mutation rate that occurs with metastasis, the spread of cancer from primary tumors via the patient's bloodstream. In order to achieve truly personalized future cancer medicine, CTCs must not only be detected and counted; the ultimate objective is to know the genetic signature or full genome of individual cells in order to develop the best therapy strategies.
ScreenCell is a fully disposable, self-contained separation device that removes all blood components from CTCs, based on size differential. “We provide a customized solution to research sites that include optimum transportation of patent samples, rapid cell separation, and validated protocols for characterization," said Georges Uzan, CSO of ScreenCell. “ScreenCell’s patented design supports a complete set of downstream analyses, including cell culture and identification of most aggressive CTC subpopulations.”
“Our team works to integrate best protocols, and we include training programs for our client labs. In addition to providing high quality and reliable products, our protocols have been validated by the world's leading cancer research centers. 50,000 devices have been shipped worldwide,” said David Znaty, CEO of ScreenCell. We invite cancer research teams to share your CTC challenge with us as we help many sites in this rapidly evolving field."
To inquire regarding how ScreenCell could benefit your cancer research program that includes Characterization of CTCs, contact:
VP Marketing and Sales
+1 978 692 9049
10 avenue Charles Peguy
95200 SARCELLES France
Tel. +33 (0)1 82 32 31 30
ScreenCell, headquartered in Paris, France is a privately held company dedicated to provide products, protocols and training support for cancer research facilities to characterize Circulating Tumor Cells and other rare cells in biological specimens. For more information please visit www.screencell.com